871345-30-1

Upstream product

• 29654-55-5 5-(hydroxymethyl)benzene-1,3-diol 
• 227023-81-6 3-benzyloxy-5-ethoxy-benxaldehyde 
• 906079-94-5 (3-benzyloxy-5-ethoxy-phenyl)-methanol 
• 906079-93-4 3-ethoxy-5-hydroxymethyl-phenol 
• 873-74-5 4-Aminobenzonitrile 

Downstream Products

• 871345-45-8 (4-cyano-phenylamino)-[3-ethoxy-5-(4-trityloxy-cyclohexyloxy)-phenyl]-acetic acid methyl ester 
• 871345-57-2 (4-carbamimidoyl-phenylamino)-[3-ethoxy-5-(4-hydroxy-cyclohexyloxy)-phenyl]-acetic acid methyl ester 
• 937018-54-7 (4-carbamimidoyl-phenylamino)-[3-ethoxy-5-(1-methanesulfonyl-piperidin-4-yloxy)-phenyl]-acetic acid methyl ester 
• 937018-43-4 4-{3-[(4-cyano-phenylamino)-methoxycarbonyl-methyl]-5-ethoxy-phenoxy}-piperidine-1-carboxylic acid tert-butyl ester 
• 937018-53-6 methyl (RS)-(4-cyano-phenylamino)-[ 3-ethoxy-5-(1-methanesulfonyl-piperidin-4-yloxy)-phenyl]-acetate 
• 783292-64-8 (4-carbamimidoyl-phenylamino)-[3-ethoxy-5-(1-methyl-piperidin-4-yloxy)-phenyl]-acetic acid methyl ester 
• 871345-56-1 (4-carbamimidoyl-phenylamino)-[3-ethoxy-5-(tetrahydro-pyran-4-yloxy)-phenyl]-acetic acid methyl ester 
• 871345-58-3 (4-Carbamimidoyl-phenylamino)-{3-ethoxy-5-[(S)-(tetrahydro-furan-3-yl)oxy]-phenyl}-acetic acid methyl ester 
• 871345-59-4 (4-Carbamimidoyl-phenylamino)-{3-ethoxy-5-[(R)-(tetrahydro-furan-3-yl)oxy]-phenyl}-acetic acid methyl ester 
• 277324-19-3 (4-cyano-phenylamino)-[3-ethoxy-5-(1-methyl-piperidin-4-yloxy)-phenyl]-acetic acid methyl ester 
• 871345-32-3 (4-cyano-phenylamino)-[3-ethoxy-5-(piperidin-4-yloxy)-phenyl]-acetic acid methyl ester 
• 871345-44-7 (4-cyano-phenylamino)-[3-ethoxy-5-(tetrahydro-pyran-4-yloxy)-phenyl]-acetic acid methyl ester 
• 277320-21-5 methyl (RS)-(4-cyano-phenylamino)-(3-ethoxy-5-trifluoromethanesulphonyloxy-phenyl)-acetate 

Relevant academic research and scientific papers

Dose-dependent antithrombotic activity of an orally active tissue factor/factor VIIa inhibitor without concomitant enhancement of bleeding propensity

The discovery of a highly potent and selective tissue factor/factor VIIa inhibitor is described. Upon oral administration of its double prodrug in the guinea pig, a dose-dependent antithrombotic effect is observed in an established model of arterial throm

Selective and orally bioavailable phenylglycine tissue factor/factor VIIa inhibitors

We describe the structure-based design and synthesis of highly potent, orally bioavailable tissue factor/factor VIIa inhibitors which interfere with the coagulation cascade by selective inhibition of the extrinsic pathway.